BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23800275)

  • 1. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis.
    Tsofack SP; Meunier L; Sanchez L; Madore J; Provencher D; Mes-Masson AM; Lebel M
    BMC Cancer; 2013 Jun; 13():303. PubMed ID: 23800275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC).
    Shuang T; Wang M; Zhou Y; Shi C
    Med Oncol; 2015 Dec; 32(12):260. PubMed ID: 26520143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
    Szabova L; Bupp S; Kamal M; Householder DB; Hernandez L; Schlomer JJ; Baran ML; Yi M; Stephens RM; Annunziata CM; Martin PL; Van Dyke TA; Weaver Ohler Z; Difilippantonio S
    PLoS One; 2014; 9(4):e95649. PubMed ID: 24748377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer.
    Cáceres-Gorriti KY; Carmona E; Barrès V; Rahimi K; Létourneau IJ; Tonin PN; Provencher D; Mes-Masson AM
    PLoS One; 2014; 9(3):e91000. PubMed ID: 24625450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma.
    Zhao Y; Chen S; Gou WF; Xiao LJ; Takano Y; Zheng HC
    Tumour Biol; 2014 Mar; 35(3):1955-64. PubMed ID: 24132590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
    Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
    Martín de la Fuente L; Malander S; Hartman L; Jönsson JM; Ebbesson A; Nilbert M; Måsbäck A; Hedenfalk I
    Int J Gynecol Pathol; 2018 Mar; 37(2):101-109. PubMed ID: 28481779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
    Li T; Xue H; Guo Y; Guo K
    Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
    Ma M; Yu N
    Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of prognoses according to non-positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
    Maeda O; Miyata-Takata T; Shibata K; Kajiyama H; Mizuno M; Tamakoshi K; Shimoyama Y; Nakamura S; Kikkawa F
    Cancer Med; 2016 Jun; 5(6):1081-92. PubMed ID: 26993048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and clinical significance of GRIM-19 in epithelial ovarian carcinoma].
    Shao YP; Cheng XD; Wan XY
    Zhonghua Fu Chan Ke Za Zhi; 2012 Oct; 47(10):751-5. PubMed ID: 23302733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.